We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Broadband Light Device Provides Effective Ulcer Treatment

By HospiMedica International staff writers
Posted on 08 Aug 2018
A novel low-level light therapy (LTTT) device could provide a new treatment option for systemic sclerosis digital ulcers (DUs), claims a new study.

Developed by researchers at Salford Royal NHS Trust (SRFT; United Kingdom), the University of Manchester (United Kingdom), and other institutions, the LTTT device is a custom-built light emitting diode (LED) lamp that emits light in the infrared (IR; 850nm), red (660nm), and ultraviolet (UV; 405nm) bands. More...
The IR light increases tissue blood flow and oxygenation; red light is believed to boost blood circulation, increasing the supply of oxygen and nutrients, and is also thought to stimulate the production of collagen; and UV light kills bacteria and reduces inflammation.

In a study to test the device, eight patients with 14 DUs between them underwent the treatment at SRFT. The DUs were irradiated with a 10J/cm2 dose twice weekly for three weeks, with follow-up at weeks four and eight. Patient and clinician DU global assessment and laser Doppler perfusion imaging both pre- and post-irradiation were used to evaluate treatment outcomes. The results revealed an average 83% improvement in DUs, with no side effects, and that DU perfusion significantly increased post-irradiation. The study was published on June 4, 2018, in the Journal of Dermatological Treatment.

“Patients having light therapy for ulcers, using lasers, are currently treated in hospital over five days and are forced to take medications which lower their blood pressure. The new therapy can be administered at home,” said lead author consultant rheumatologist Michael Hughes, MD, of the University of Manchester. “We believe this technology is a game changer; the implications are huge. In the next six to twelve months we shall be refining the machine, and within 12 months we hope to trialing it on diabetic ulcers.”

DUs are a common visible manifestation of the progressive vascular disease that characterizes systemic sclerosis disease process. DUs not only impact significantly on patients’ quality of life and hand function, but are also a biomarker of internal organ involvement and of disease severity. DUs are often exquisitely painful and are associated with high levels of hand and global disability. They are often infected and slow to heal, especially in the presence of calcinosis, and can also be associated with an underlying bone infection.

Related Links:
Salford Royal NHS Trust
University of Manchester

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.